Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice | Xenon Pharmaceuticals Inc.

Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice

September 6, 2026

Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice 346.5 KB

Tags

Azetukalner in Epilepsy

Congress: European Epilepsy Congress (September 6, 2026)
Authors: Becker DA, et al.
Encore of AES 2025

Investor inquiries

Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com

Request Information

Email alerts

Sign up here to receive email alerts from Xenon Pharmaceuticals